– UK, London – MGC Pharmaceuticals Ltd (LON: MXC | ASX: MXC), a European-based pharmaceutical company, today announced the appointment of Layton Mills to its Board as a Non-Executive Director effective immediately.
About Layton Mills
Layton Mills is an experienced life-sciences executive, having worked in the biotechnology and life sciences industries for over 15 years, developing significant experience across human and animal health in pharmaceutical and consumer healthcare.
Layton Mills is the founder of CannPal Animal Therapeutics Pty Ltd, an Animal Health Company developing cannabinoid-based veterinary medicines for FDA-CVM registration, which he led through an Initial Public Offering on the Australian Stock Exchange, followed by an acquisition by AusCann Group Holdings in 2021 where he served as CEO. Mr. Mills is also the founder and Managing Director of Subgenix Lifesciences, an early-stage biotechnology Company using conventional drug development strategies to unlock the broader therapeutic potential of psychedelic compounds for rare and underserved health needs.
He has extensive international business experience having been involved in corporate business activities across Europe, Asia, and North America, including government-led trade incentives with the Canberra Business Chamber.
About MGC Pharma
MGC Pharmaceuticals Ltd is a European-based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant-inspired medicines, combining in-house research with innovative technologies to find or produce treatments for unmet medical conditions.
The Company’s founders and executives are critical figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America, and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimize the development of targeted plant-inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland. It has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Source: https://mgcpharma.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
